TY - JOUR
T1 - Data Descriptor
T2 - Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells
AU - Ferrer, Marc
AU - Gosline, Sara J.C.
AU - Stathis, Marigo
AU - Zhang, Xiaohu
AU - Guo, Xindi
AU - Guha, Rajarshi
AU - Ryman, Dannielle A.
AU - Wallace, Margaret R.
AU - Kasch-Semenza, Laura
AU - Hao, Haiping
AU - Ingersoll, Roxann
AU - Mohr, David
AU - Thomas, Craig
AU - Verma, Sharad
AU - Guinney, Justin
AU - Blakeley, Jaishri O.
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/6/12
Y1 - 2018/6/12
N2 - Neurofibromatosis type I (NF1) is an autosomal dominant genetic condition characterized by peripheral nervous system tumors (PNSTs), including plexiform neurofibromas (pNFs) that cause nerve dysfunction, deformity, pain damage to adjacent structures, and can undergo malignant transformation. There are no effective therapies to prevent or treat pNFs. Drug discovery efforts are slowed by the 'benign' nature of the Schwann cells that are the progenitor cells of pNF. In this work we characterize a set of pNF-derived cell lines at the genomic level (via SNP Arrays, RNAseq, and Whole Exome- Sequencing), and carry out dose response-based quantitative high-throughput screening (qHTS) with a collection of 1,912 oncology-focused compounds in a 1536-well microplate cell proliferation assays. Through the characterization and screening of NF1(-/-), NF1(+/+) and NF1(+/-) Schwann cell lines, this resource introduces novel therapeutic avenues for the development for NF1 associated pNF as well as all solid tumors with NF1 somatic mutations. The integrated data sets are openly available for further analysis at http://www.synapse.org/pnf Cell Culture.
AB - Neurofibromatosis type I (NF1) is an autosomal dominant genetic condition characterized by peripheral nervous system tumors (PNSTs), including plexiform neurofibromas (pNFs) that cause nerve dysfunction, deformity, pain damage to adjacent structures, and can undergo malignant transformation. There are no effective therapies to prevent or treat pNFs. Drug discovery efforts are slowed by the 'benign' nature of the Schwann cells that are the progenitor cells of pNF. In this work we characterize a set of pNF-derived cell lines at the genomic level (via SNP Arrays, RNAseq, and Whole Exome- Sequencing), and carry out dose response-based quantitative high-throughput screening (qHTS) with a collection of 1,912 oncology-focused compounds in a 1536-well microplate cell proliferation assays. Through the characterization and screening of NF1(-/-), NF1(+/+) and NF1(+/-) Schwann cell lines, this resource introduces novel therapeutic avenues for the development for NF1 associated pNF as well as all solid tumors with NF1 somatic mutations. The integrated data sets are openly available for further analysis at http://www.synapse.org/pnf Cell Culture.
UR - http://www.scopus.com/inward/record.url?scp=85048416367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048416367&partnerID=8YFLogxK
U2 - 10.1038/sdata.2018.106
DO - 10.1038/sdata.2018.106
M3 - Article
C2 - 29893754
AN - SCOPUS:85048416367
SN - 2052-4463
VL - 5
JO - Scientific Data
JF - Scientific Data
M1 - 180106
ER -